Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
Petar Seferović, Andrew J.S. Coats, Piotr Ponikowski, et al.
European Journal of Heart Failure (2019) Vol. 22, Iss. 2, pp. 196-213
Open Access | Times Cited: 155

Showing 1-25 of 155 citing articles:

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3599-3726
Open Access | Times Cited: 8643
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa McDonagh, Marco Metra, Marianna Adamo, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 1, pp. 4-131
Open Access | Times Cited: 1501
Basic Mechanisms of Diabetic Heart Disease
Rebecca H. Ritchie, E. Dale Abel
Circulation Research (2020) Vol. 126, Iss. 11, pp. 1501-1525
Open Access | Times Cited: 459
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Carolyn F. Deacon
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 11, pp. 642-653
Closed Access | Times Cited: 266
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology
Giuseppe Rosano, Brenda Moura, Marco Metra, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 6, pp. 872-881
Open Access | Times Cited: 227
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae‐Seung Yun, Seung‐Hyun Ko
Metabolism (2021) Vol. 123, pp. 154838-154838
Open Access | Times Cited: 175
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Maciej Banach, Paweł Burchardt, Krzysztof Chlebus, et al.
Archives of Medical Science (2021) Vol. 17, Iss. 6, pp. 1447-1547
Open Access | Times Cited: 132
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
Daniela Tomasoni, Gregg C. Fonarow, Marianna Adamo, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 3, pp. 431-441
Open Access | Times Cited: 107
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
Revista Española de Cardiología (2022) Vol. 75, Iss. 6, pp. 523.e1-523.e114
Closed Access | Times Cited: 89
Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024

Cardiology Discovery (2025)
Open Access | Times Cited: 3
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology
Petar Seferović, Gabriele Fragasso, Mark C. Petrie, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 9, pp. 1495-1503
Open Access | Times Cited: 122
Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics
Claudio Napoli, Giuditta Benincasa, Francesco Donatelli, et al.
American Heart Journal (2020) Vol. 224, pp. 113-128
Open Access | Times Cited: 80
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5863-5863
Open Access | Times Cited: 77
Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
Alexandros Kasiakogias, Enrico Agabiti Rosei, Miguel Camafort, et al.
Journal of Hypertension (2021) Vol. 39, Iss. 8, pp. 1522-1545
Open Access | Times Cited: 56
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care
Daniela Tomasoni, Julie K.K. Vishram‐Nielsen, Matteo Pagnesi, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 3, pp. 1507-1523
Open Access | Times Cited: 51
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
Massimo Piepoli, Marianna Adamo, Andrea Barison, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 1, pp. 143-168
Open Access | Times Cited: 51
Heart failure: an update from the last years and a look at the near future
Mauro Riccardi, Antonio Maria Sammartino, Massimo Piepoli, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 6, pp. 3667-3693
Open Access | Times Cited: 49
The FORTA (Fit fOR The Aged) List 2021: Fourth Version of a Validated Clinical Aid for Improved Pharmacotherapy in Older Adults
Farhad Pazan, Christel Weiß, Martin Wehling, et al.
Drugs & Aging (2022) Vol. 39, Iss. 3, pp. 245-247
Open Access | Times Cited: 46
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Melanie J. Davies, Heinz Drexel, François R. Jornayvaz, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
Heart failure in the last year: progress and perspective
Daniela Tomasoni, Marianna Adamo, Markus S. Anker, et al.
ESC Heart Failure (2020) Vol. 7, Iss. 6, pp. 3505-3530
Open Access | Times Cited: 68
Acute heart failure: More questions than answers
Daniela Tomasoni, Carlo Lombardi, Marco Sbolli, et al.
Progress in Cardiovascular Diseases (2020) Vol. 63, Iss. 5, pp. 599-606
Closed Access | Times Cited: 65
Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
Alice M. Jackson, Rasmus Rørth, Jiankang Liu, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 3, pp. 497-509
Open Access | Times Cited: 54
Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Yi-Wen Yu, Xue-Mei Zhao, Yun-Hong Wang, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 41
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
Marta Baviera, Andreana Foresta, Pierluca Colacioppo, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 29
A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review PART II—Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory
Marcin Piechocki, Tadeusz Przewłocki, Piotr Pieniążek, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1508-1508
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top